Exelixis
EXEL
#1649
Rank
NZ$22.92 B
Marketcap
NZ$91.19
Share price
-0.24%
Change (1 day)
32.13%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): NZ$5.35

According to Exelixis's latest financial reports the company's current EPS (TTM) is NZ$5.39. In 2025 the company made an earnings per share (EPS) of NZ$4.97.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$5.357.67%
2025NZ$4.97
2023NZ$1.1214.61%
2022NZ$0.98-22.97%
2021NZ$1.27100%
2020NZ$0.64-65.09%
2019NZ$1.82-53.91%
2018NZ$3.96333.96%
2017NZ$0.91-260.61%
2016NZ-$0.57-58.75%
2015NZ-$1.38-42.45%
2014NZ-$2.395.3%
2013NZ-$2.27

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
NZ$15.03 179.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$2.25-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$24.91 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$4.40-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
NZ$6.12 13.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$6.13 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
NZ$6.69 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
NZ-$6.31-217.25%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
NZ-$1.45-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA